Lupitas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.70 M
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -5.94%
- Profit Growth 236.24%
- Ebitda 5469.51%
- Net Worth 4.99%
- Total Assets 11.67%
About Lupitas Pharmaceuticals
Lupitas Pharmaceuticals Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 31 March 2014 and has a history of Ten years and ten months. Its registered office is in Surat, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.70 M, as per Ministry of Corporate Affairs (MCA) records.
Pravinbhai Vekariya, Ghanshyam Laheri, Hetalben Bhadiyadara, and Three other members serve as directors at the Company.
Company Details
-
Location
Surat, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24100GJ2014PTC079490
-
Company No.
079490
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
31 Mar 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
What products or services does Lupitas Pharmaceuticals Private Limited offer?
Lupitas Pharmaceuticals Private Limited offers a wide range of products and services, including Skin Care, Facewash.
Who are the key members and board of directors at Lupitas Pharmaceuticals?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pravinbhai Vekariya
|
Director | 31-Mar-2014 | Current |
|
Kishorkumar Kachhadiya
|
Director | 12-Jun-2015 | Current |
|
Ghanshyam Laheri
|
Director | 31-Mar-2014 | Current |
|
Hetalben Bhadiyadara
|
Director | 12-Jun-2015 | Current |
|
Ashish Pandya
|
Director | 18-Sep-2015 | Current |
|
Pareshkumar Dhameliya
|
Director | 04-Aug-2021 | Current |
Financial Performance of Lupitas Pharmaceuticals.
Lupitas Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.94% decrease. The company also saw a substantial improvement in profitability, with a 236.24% increase in profit. The company's net worth moved up by a moderate rise of 4.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lupitas Pharmaceuticals?
In 2023, Lupitas Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Delphard Healthcare Private LimitedPareshkumar Dhameliya is a mutual person
-
Elecore Distributor India LlpPravinbhai Vekariya is a mutual person
-
Mediox Life Science Llp
Pravinbhai Vekariya is a mutual person
-
Gama Surgical India Private Limited
Pravinbhai Vekariya is a mutual person
-
Times Vacanza Private Limited
Pareshkumar Dhameliya is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lupitas Pharmaceuticals?
Lupitas Pharmaceuticals has a workforce of 9 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lupitas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lupitas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
